Emir Festic1, Vikas Bansal1, Ena Gupta2, Paul D Scanlon3. 1. a Pulmonary and Critical Care Medicine , Mayo Clinic, Jacksonville , FL , USA. 2. b Internal Medicine, University of Florida/SHANDS , Jacksonville , FL , USA. 3. c Pulmonary and Critical Care Medicine, Mayo Clinic , Rochester , MN , USA.
Abstract
BACKGROUND: Inhaled corticosteroids are commonly prescribed for patients with severe COPD. They have been associated with increased risk of pneumonia but not with increased pneumonia-associated or overall mortality. METHODS: To further examine the effects of inhaled corticosteroids on pneumonia incidence, and mortality in COPD patients, we searched for potentially relevant articles in PubMed, Medline, CENTRAL, EMBASE, Scopus, Web of Science and manufacturers' web clinical trial registries from 1994 to February 4, 2014. Additionally, we checked the included and excluded studies' bibliographies. We subsequently performed systematic review and meta-analysis of included randomized controlled trials and observational studies on the topic. RESULTS: We identified 38 studies: 29 randomized controlled trials and nine observational studies. The estimated unadjusted risk of pneumonia was increased in randomized trials: RR 1.61; 95% CI 1.35-1.93, p < 0.001; as well as in observational studies: OR 1.89; 95% CI 1.39-2.58, p < 0·001. Six randomized trials and seven observational studies were useful in estimating unadjusted risk of pneumonia -case-fatality: RR 0.91; 95% CI 0.52-1.59, p = 0.74; and OR 0.72; 95% CI 0.59-0.88, p = 0.001, respectively. Twenty-nine randomized trials and six observational studies allowed estimation of unadjusted risk of overall mortality: RR 0.95; 95% CI 0.85-1.05, p = 0.31; and OR 0.79; 95% CI 0.65-0.97, p = 0.02, respectively. CONCLUSIONS: Despite a substantial and significant increase in unadjusted risk of pneumonia associated with inhaled corticosteroid use, pneumonia fatality and overall mortality were found not to be increased in randomized controlled trials and were decreased in observational studies.
BACKGROUND: Inhaled corticosteroids are commonly prescribed for patients with severe COPD. They have been associated with increased risk of pneumonia but not with increased pneumonia-associated or overall mortality. METHODS: To further examine the effects of inhaled corticosteroids on pneumonia incidence, and mortality in COPDpatients, we searched for potentially relevant articles in PubMed, Medline, CENTRAL, EMBASE, Scopus, Web of Science and manufacturers' web clinical trial registries from 1994 to February 4, 2014. Additionally, we checked the included and excluded studies' bibliographies. We subsequently performed systematic review and meta-analysis of included randomized controlled trials and observational studies on the topic. RESULTS: We identified 38 studies: 29 randomized controlled trials and nine observational studies. The estimated unadjusted risk of pneumonia was increased in randomized trials: RR 1.61; 95% CI 1.35-1.93, p < 0.001; as well as in observational studies: OR 1.89; 95% CI 1.39-2.58, p < 0·001. Six randomized trials and seven observational studies were useful in estimating unadjusted risk of pneumonia -case-fatality: RR 0.91; 95% CI 0.52-1.59, p = 0.74; and OR 0.72; 95% CI 0.59-0.88, p = 0.001, respectively. Twenty-nine randomized trials and six observational studies allowed estimation of unadjusted risk of overall mortality: RR 0.95; 95% CI 0.85-1.05, p = 0.31; and OR 0.79; 95% CI 0.65-0.97, p = 0.02, respectively. CONCLUSIONS: Despite a substantial and significant increase in unadjusted risk of pneumonia associated with inhaled corticosteroid use, pneumonia fatality and overall mortality were found not to be increased in randomized controlled trials and were decreased in observational studies.
Authors: Paul van der Valk; Evelyn Monninkhof; Job van der Palen; Gerhard Zielhuis; Cees van Herwaarden Journal: Am J Respir Crit Care Med Date: 2002-09-05 Impact factor: 21.405
Authors: E F M Wouters; D S Postma; B Fokkens; W C J Hop; J Prins; A F Kuipers; H R Pasma; C A J Hensing; E C Creutzberg Journal: Thorax Date: 2005-06 Impact factor: 9.139
Authors: Donald A Mahler; Patrick Wire; Donald Horstman; Chai-Ni Chang; Julie Yates; Tracy Fischer; Tushar Shah Journal: Am J Respir Crit Care Med Date: 2002-10-15 Impact factor: 21.405
Authors: R A Pauwels; C G Löfdahl; L A Laitinen; J P Schouten; D S Postma; N B Pride; S V Ohlsson Journal: N Engl J Med Date: 1999-06-24 Impact factor: 91.245
Authors: W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson Journal: Eur Respir J Date: 2003-01 Impact factor: 16.671
Authors: Rajan Murgai; Anthony D'Oro; Patrick Heindel; Kyle Schoell; Kaku Barkoh; Zorica Buser; Jeffrey C Wang Journal: Int J Spine Surg Date: 2018-12-21
Authors: Christer Janson; Gunnar Johansson; Björn Ställberg; Karin Lisspers; Petter Olsson; Dorothy L Keininger; Milica Uhde; Florian S Gutzwiller; Leif Jörgensen; Kjell Larsson Journal: Respir Res Date: 2018-09-10